Total of $14 million (1.87 billion JPY) was raised in the Series C round, and cumulative $35 million (4.6 billion JPY, including grants) has been raised to date. Metcela is aiming to create new therapeutic options for heart failure by establishing an ecosystem for autologous cell therapy.

Metcela Inc. is a pioneer biotechnology company founded in Japan. Metcela aims to be the first to commercialize biological products that heal damaged heart muscle to treat heart failure.

Metcela Inc. Completes The Series C Financing Of Total $14 Million

Description

Company Information

Metcela Inc. Completes The Series C Financing Of Total $14 Million

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information